Get the Stockscreener App
0.9499
3.13%
0.0288
After Hours:
.95
0.000101
+0.01%
Xortx Therapeutics Inc stock is traded at $0.9499, with a volume of 51,934.
It is up +3.13% in the last 24 hours and down -10.39% over the past month.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
See More
Previous Close:
$0.9211
Open:
$0.93
24h Volume:
51,934
Relative Volume:
1.06
Market Cap:
$3.60M
Revenue:
-
Net Income/Loss:
$-736.70K
P/E Ratio:
-94.99
EPS:
-0.01
Net Cash Flow:
$-4.14M
1W Performance:
-2.57%
1M Performance:
-10.39%
6M Performance:
-21.50%
1Y Performance:
-63.32%
1-Day Range:
$0.90
$0.95
1-Week Range:
$0.90
$1.00
52-Week Range:
$0.802
$2.9799
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.9499 | 3.69M | 0 | -736.70K | -4.14M | -0.01 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
XORTX Therapeutics looks to raise $3M through private placement - MSN
XRTX Initiates $3 Million Private Placement to Fund Key Projects - GuruFocus
XORTX Announces $3 Mln Private Placement To Advance Gout And Kidney Disease Program - Nasdaq
MT Newswires Canada Stocks To Watch: Endeavour Mining; Quantum BioPharma; XORTX Therapeutics - marketscreener.com
XORTX Announces USD $3 Million Offering - GlobeNewswire
XORTX Therapeutics Announces $3 Million Offering to Advance Gout Programs - TipRanks
Late-Stage Biotech XORTX Secures $3M Funding to Advance Novel Gout Treatment Program - Stock Titan
XORTX Therapeutics Inc. announced that it expects to receive $2.999999 million in funding - marketscreener.com
XORTX Therapeutics reports Q1 financials to SEC By Investing.com - Investing.com South Africa
XORTX Therapeutics Reports Q1 2025 Financial Results - TipRanks
XORTX Therapeutics reports Q1 financials to SEC - Investing.com
XORTX Therapeutics Delays Yearly Report Filing - TipRanks
XORTX Therapeutics Higher in U.S. Pre-market Trading, Says FDA Type B Meeting Positive - marketscreener.com
XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance - TipRanks
XORTX Therapeutics Provides Update On FDA Type B Meeting Request - marketscreener.com
XORTX Therapeutics Brief: Providing Update on FDA Type B Meeting Request - marketscreener.com
XORTX Provides Update on FDA Type B Meeting Request - GlobeNewswire
XORTX Therapeutics Inc. Provides Update on FDA Type B Meeting Request - marketscreener.com
FDA Green Lights XORTX Path to NDA: Key Steps Revealed for Novel Gout Treatment XORLO - Stock Titan
XORTX Therapeutics Inc. Announces Grant of European Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs - marketscreener.com
XORTX Secures European Patent for Gout and Kidney Disease Therapies - TipRanks
XORTX Announces Grant of European Patent - GlobeNewswire
XORTX Secures Game-Changing European Patent for Gout and Kidney Disease Treatments - Stock Titan
XORTX Therapeutics receives Nasdaq notice for non-compliance - MSN
XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge - GuruFocus
XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency - MSN
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewswire
XORTX Faces Nasdaq Price Compliance Challenge: 180 Days to Avoid Delisting Risk - Stock Titan
XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX) - The Globe and Mail
1 Defense Stock to Buy for Protection During These Uncertain Times - The Globe and Mail
XORTX Therapeutics Releases Annual Information Form for 2024 - TipRanks
XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses - TipRanks
XORTX Announces Update for Discussion with the FDA - GlobeNewswire
XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks
XORTX Therapeutics Brief: Announced Update for Discussion with the FDA -March 19, 2025 at 07:14 am EDT - Marketscreener.com
XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com
XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan
Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News
XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks
XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire
Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com
XORTX to Present at Microcap Conference - GlobeNewswire
XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks
Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan
XORTX Therapeutics Announces Auditor Transition - MSN
XORTX Announces Change of Auditor - TipRanks
XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.70%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):